- Raised Seed round led by TLV Partners, Nov 2019
About
Canopy Immuno-Therapeutics is a pre-clinical stage biotech company developing a novel immunotherapeutic approach for dozens of immune-related disorders. The company focuses on developing and commercializing biopharmaceuticals based on a novel immunotherapeutic approach for autoimmunity. Their proprietary Reverse-Immunization platform aims to eliminate antigen-specific immunity, providing non-immunosuppressive and potentially curative treatments. Canopy's solution involves Antigen-drug conjugates (AgDCs) that selectively clear pathological antibodies and autoreactive B-cells while preserving protective immunity. The company's vision is to develop best-in-class, non-immunosuppressive, and potentially curative therapies for antibody-mediated autoimmune conditions.
Funding history · 1 round · — total
Q&A
- What is Canopy Immuno-Therapeutics' primary focus?
- Canopy Immuno-Therapeutics is a pre-clinical stage biotech company focused on developing a new class of biologics for the elimination of antigen-specific immunity, aiming to provide non-immunosuppressive treatments for autoimmune, allergic, and other antibody-mediated conditions using its proprietary Reverse-Immunization platform.
- When was Canopy Immuno-Therapeutics founded?
- Canopy Immuno-Therapeutics was founded in December 2019.
- What is the current employee count for Canopy Immuno-Therapeutics?
- Canopy Immuno-Therapeutics has 6 employees, falling within the 1-10 employee bucket.
- Which investors participated in Canopy Immuno-Therapeutics' funding round in February 2024?
- TLV Partners participated in Canopy Immuno-Therapeutics' funding round in February 2024.
- What is Canopy Immuno-Therapeutics' current funding stage?
- Canopy Immuno-Therapeutics is currently in its Series A funding stage.
- What sector does Canopy Immuno-Therapeutics primarily operate in?
- Canopy Immuno-Therapeutics' primary sector is Health Tech & Life Sciences, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.
- What is the product stage of Canopy Immuno-Therapeutics?
- Canopy Immuno-Therapeutics' product is currently in the R&D stage.
- What technologies does Canopy Immuno-Therapeutics utilize?
- Canopy Immuno-Therapeutics utilizes Platforms & Interfaces, Software, and Artificial Intelligence technologies.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | canopy-biotech.com |
|---|---|
| linkedin.com/in/kfir-oved-96b2201b |
Identifiers & details
| Founded | 2019-12 |
|---|---|
| Employees (exact) | 6 |
Radar intelligence
Patents
| EPO | 9 |
|---|
Web history (Wayback)
| Domain | canopy-biotech.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516091204 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2019-10-02 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 2 — shares_capital (2) |
| Registered address | הגלים 5 מגדים |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-17 | העברת מניות |
| 2025-11-02 | הקצאת מניות |